Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011:2:331-2.
doi: 10.7150/jca.2.331. Epub 2011 Jun 1.

Chimeric Antigen Receptor Therapy for B-cell Malignancies

David L Porter  1 , Michael Kalos, Zhaohui Zheng, Bruce Levine, Carl June
Affiliations

Chimeric Antigen Receptor Therapy for B-cell Malignancies

David L Porter et al. J Cancer. 2011.

Abstract

We presented data showing that the CART-19 cells expressing the 4-1BB signaling domain can have unprecedented and massive in-vivo expansion, traffic to tumor sites, persist long term in vivo, and induce rapid and potent anti-tumor activity in chemotherapy refractory CLL patients.

Keywords: B-cell Malignancies; CART-19; Chimeric Antigen Receptor Therapy.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: The authors have declared that no conflict of interest exists.

References

    1. Irving BA, Weiss A. The cytoplasmic domain of the T cell receptor zeta chain is sufficient to couple to receptor-associated signal transduction pathways. Cell. 1991;64:891–901. - PubMed
    1. Sadelain M, Brentjens R, Riviere I. The promise and potential pitfalls of chimeric antigen receptors. CurrOpinImmunol. 2009;21:215–223. - PMC - PubMed
    1. Lamers CH, Willemsen R, van Elzakker P. et al. Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells. Blood. 2011;117:72–82. - PubMed
    1. Kochenderfer J, Wilson W, Janik J. et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically-engineered to recognize CD19. Blood. 2010;116(20):4099–102. - PMC - PubMed
    1. Uckun FM, Jaszcz W, Ambrus JL. et al. Detailed studies on expression and function of CD19 surface determinant by using B43 monoclonal antibody and the clinical potential of anti-CD19 immunotoxins. Blood. 1988;71:13–29. - PubMed